Kristin Clemens
Psychiatric/Mental Health · Gaithersburg, MDNPI 1154961381
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 69.4% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $15,923, more than ten times the $246 reported in 2021. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $126.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- Janssen Scientific Affairs, LLC$7K
- Otsuka America Pharmaceutical, Inc.$941
- Axsome Therapeutics, Inc.$552
- Teva Pharmaceuticals USA, Inc.$518
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$423
- plus $2K from 17 others
What the payments were for
- Consulting fees$6,66018%
- Speaking & faculty fees$19,25053%
- Travel & lodging$3,98811%
- Food & beverage$6,13317%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 119 | $25,051 |
| Janssen Scientific Affairs, LLC | 10 | $6,694 |
| Otsuka America Pharmaceutical, Inc. | 40 | $941 |
| Axsome Therapeutics, Inc. | 20 | $552 |
| Teva Pharmaceuticals USA, Inc. | 9 | $518 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $423 |
| Alkermes, Inc. | 15 | $312 |
| Lundbeck LLC | 12 | $282 |
| Johnson & Johnson | 6 | $221 |
| Biogen | 2 | $215 |
| Sunovion Pharmaceuticals Inc. | 8 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $174 |
| Acadia Pharmaceuticals Inc | 1 | $110 |
| Vanda Pharmaceuticals Inc. | 4 | $86 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Bausch Health US, LLC | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Noven Therapeutics, LLC | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$21,100
- SPRAVATO$6,760
- Austedo XR$239
- REXULTI$238
- ABILIFY MAINTENA$123
- ABILIFY ASIMTUFII$123
- NUPLAZID$110
- AUSTEDO$106
- CAPLYTA$100
How this compares
$36,077 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 19 | $22,361 |
| Trimipramine Maleate | 12 | $6,651 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $1,557 |
| Fluvoxamine Maleate | 15 | $1,475 |
| Clozapine | 11 | $1,297 |
| Quetiapine Fumarate | 15 | $961 |
| Fluoxetine Hcl | 30 | $843 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 27 | $585 |
| Clonazepam | 59 | $573 |
| Divalproex Sodium | 13 | $450 |
| Gabapentin | 14 | $391 |
| Escitalopram Oxalate | 36 | $246 |
| Alprazolam | 15 | $74 |
| Lorazepam | 17 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $221 | $22,36119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Gaithersburg
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
- Anyinke AtabongRockville$15K
- Zenatsehay GebretsadikColumbia$15K
- Travis BairdGlen Burnie$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.